metricas
covid
Medicina Clínica (English Edition) Reply to: “Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatme...
Journal Information

Statistics

Follow this link to access the full text of the article

Letter to the Editor
Reply to: “Effectiveness of alirocumab and evolocumab (PCSK9i) for the treatment of hypercholesterolemia”
Respuesta a: “Efectividad de alirocumab y evolocumab (PCSK9i) en el tratamiento de la hipercolesterolemia”
Montserrat Boscha,b,c, Elena Ballarína,c, Immaculada Danésa,b,c,
Corresponding author
immaculada.danes@vallhebron.cat

Corresponding author.
a Clinical Pharmacology Department, Vall d’Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain
b Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain
c Clinical Pharmacology Research Group, Vall d’Hebron Institut De Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain
Read
38
Times
was read the article
0
Total PDF
38
Total HTML
Share statistics
Article information
ISSN: 23870206
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 38 0 38

Follow this link to access the full text of the article

Article options
Tools